

Curriculum Vitae - Laurence de Leval - January 2025



Personal information

First Name Laurence
Last Name de Leval
Nationality Swiss & Belgian
Language French
Address Institute of Pathology, CHUV, Rue du Bugnon 25, CH-1011 Lausanne
Phone nr +41 21 314 71 94 / +41 79 556 37 14
Researcher ID M-4889-2017

Current positions

Director of Clinical Pathology (Chef de Service) and Full Professor, University of Lausanne
Institute of Pathology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
Invited professor, University of Liège, Belgium
Co-chair of the T-cell lymphoma working group of the LYSA (Lymphoma Study Association)
Scientific Secretary of the European Association for Haematopathology

Previous positions

2008-2009 Professor of Clinics, University of Liège, Belgium
2007-2009 Permanent Research Associate of the National Fund for Scientific Research (FNRS)
2004-2009 Maître de Conférences, University of Liège
2000-2009 Associate Pathologist, CHU Liège
1998-2000 Permanent Research Associate of the FNRS
1998-2000 Post-doctoral Researcher in Hematopathology and Resident in Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
1994-1998 Research Fellow of the FNRS and Resident in Pathology, CHU Liège

Education

2015 Board certified in Molecular Pathology (FMH, Switzerland)
2010 Board certified in Pathology (FMH, Switzerland)
2007 Agrégation de l'Enseignement Supérieur, University of Liège
2000 Board certified in Pathologic Anatomy and Cytology, Belgium
1999 United States Medical Licensing Examination, Philadelphia, USA
1998 PhD in Biomedical Sciences, University of Liège, *Summa cum laude* + Jury's congratulations
1994 Medical Doctor, University of Liège, Belgium, *Summa cum laude* + Jury's congratulations

Scientific awards, bursaries, memberships (selected)

2015 Elected member of the Scientific board, the International Workshop for Non-Hodgkin Lymphomas
2011 Elected member, the International Lymphoma Study Group
2009 Prize of the Inbev-Latour Foundation for clinical research (75,000 euros)
2008 Benjamin Castleman award of the United States and Canadian Academy of Pathology, in recognition of the best paper published in the field of pathology (1,500 USD)

Expert activities

Invited lectures at many national and international meetings organized by Pathology, Hematology or Oncology Societies; lecturer at the Educational Programme sessions of the American and European Societies of Hematology; lecturer at different pathology courses in Europe and America.

Editorial activities: member of the Editorial Board of Virchows Archiv, Frontiers in Oncology, Journal of Haematopathology, Modern Pathology, Haematologica; Associate editor of Journal of Clinical Pathology.

Editor The International Consensus Classification of myeloid and lymphoid neoplasms, co-editors DA Arber, JR Cook, L de Leval, JR Goodlad, RP Hasserjian, RL King, HM Kvasnicka, A Orazi, Wolters Kluvers, Philadelphia, 2025

Ad hoc reviewer for Journals: Annals of Hematology, Blood, Blood Advances, Clinical Cancer Research, Haematologica, Histopathology, The Journal of Haematopathology, Journal of Pathology, Leukemia, Modern Pathology, New England Journal of Medicine, Virchow Archives.

Scientific expert for review of grant applications to different granting agencies and foundations, incl. Leukemia and Lymphoma Foundation, and the Institut National du Cancer (France), CALYM Janssen, Swiss Cancer Research foundation, Singapore National Research Foundation, AstraZeneca Foundation, the Funds for Scientific Research in Belgium

Research funding in the past five years as investigator or c-investigator was obtained from the Ligue Suisse du Cancer, European FP7 grant, Swiss National Foundation, Swiss Personalized Health Network, Owkin, the Loterie Romande, Porphyrogenesis Foundation.

Major contributions to science

The research of our group has contributed several major advances in the characterization of T-cell lymphoma pathology with respect to their molecular and genetic features, phenotypic attributes and clinico-pathologic correlations.

Follicular helper T-cell lymphomas (TFH lymphomas) By performing gene expression profiling experiments, we demonstrated the origin of AITL from TFH cells. This characteristic as an important determinant of the biology of the disease, was thereafter incorporated into the definition of AITL. Subsequent works from us and others demonstrated an expanded spectrum of TFH-derived lymphomas, a concept adopted by the 2017 WHO classification and confirmed and reinforced in the recent 2022 classifications, with the recognition of three subtypes, AI, NOS, and follicular. The morphologic and phenotypic features of the latter subtype had been described by us several years earlier. Further, by performing whole exome and targeted sequencing studies we reported recurrent *TET2 DNMT3A* and *IDH2* mutations in AITL and other TFH lymphomas, and multiple recurrent activating mutations affecting proximal and/or distal elements of the T-cell receptor signaling pathway in half of the patients. The delineation of TFH lymphoma as a distinct group of PTCL is clinically relevant as the TFH phenotype emerges as a biomarker of response to epigenetic drugs (demethylating agents and HDAC inhibitors)

In *type II enteropathy-associated T-cell lymphoma (EATL)/monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL)*, an aggressive intestinal T-cell lymphoma, we discovered alterations of the *SETD2* gene encoding a non-redundant H3K36-specific trimethyltransferase, in >90% of the cases, mainly by loss-of-function mutations and/or loss of 3p21.31. We validated the use of H3K36 trimethylation immunohistochemistry as a surrogate of defective SETD2 function. The genomic landscape of MEITL also comprises recurrent mutations in *STAT5B*, *JAK3* and *TP53*, with *STAT5B* and *TP53* mutations being associated with adverse clinical outcome in a large series of cases. We also documented a morphologic spectrum of the entity comprising a significant subset of atypical cases deviating from the original description of the disease, and associated with a worse outcome.

Research output 2018-2025

Original articles

1. Kfoury A, Armaro M, Collodet C, Sordet-Dessimoz J, Giner MP, Christen S, Moco S, Leleu M, **de Leval L**, Koch U, Trumpp A, Sakamoto K, Beermann F, Radtke F. AMPK promotes survival of c-Myc-positive melanoma cells by suppressing oxidative stress. *The EMBO Journal*. 2018; 37(5): e97673.
2. Steiner R, Kridel R, Giostra E, McKee T, Achermann R, Mueller N, Manuel O, Dickenmann M, Schuurmans MM, **de Leval L**, Fehr T, Tinguely M, Binet I, Cogliatti S, Haralamvieva E, Koller M, The Swiss Transplant Cohort Study S, Dietrich PY. Low 5-year cumulative incidence of post-transplant lymphoproliferative disorders after solid organ transplantation in Switzerland. *Swiss Medical Weekly*. 2018; 148:w14596.
3. Herfs M, Roncarati P, Koopmansch B, Peulen O, Bruyère D, Lebeau A, Hendrick E, Hubert P, Poncin A, Penny W, Piazzon N, Monnier F, Guénat D, Mouglin C, Pretet JL, Segers K, Lambert F, Bours V, **de Leval L**, Valmary-Degano S, Quick CM, Crum C, Delvenne P. A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalized medicine. *British Journal of Cancer* 2018; 118(10): 1302-1312.
4. Monteiro I, Viganò S, Faouzi M, Treilleux I, Michielin O, Menetrieru-Caux C, Caux C, Romero P, **de Leval L**. CD73 expression and clinical significance in metastatic melanoma. *Oncotarget*. 2018; 9(42):26659-26669.
5. Dupuy A, Lemonnier F, Fataccioli V, Martin N, Robe C, Pelletier R, Poullot E, Mokhtari K, Rousselet MC, Traverse-Glehen A, Delarue R, Tournilhac O, Delfau-Larue MH, Haioun C, Copie-Bergman C, **de Leval L**, Pujals A, Gaulard P. Multiple ways to detect IDH2 mutations in angioimmunoblastic T-cell lymphoma: from immunohistochemistry to Next Generation Sequencing. *Journal of Molecular Diagnostics*. 2018; 20(5):677-685.
6. Sujobert P, Le Bris Y, **de Leval L**, Gros A, Merlio JP, Pastoret C, Huet S, Sarkozy C, Davi F, Callanan M, Thieblemont C, Sibon D, Asnafi V, Preudhomme C, Gaulard P, Jardin F, Salles G, Macintyre E. The Need for a Consensus Next-generation Sequencing Panel for Mature Lymphoid Malignancies. *HemaSphere*. 2018; 3 (1): e169.
7. Chen BJ, Ruminy P, Roth CG, Bisig B, Mankel B, Steinhilber J, Bohers E, Jardin F, Fend F, Swerdlow SH, Copie-Bergman C, **de Leval L**, Quintanilla-Martinez L. Cyclin D1-positive Mediastinal Large B-Cell Lymphoma With Copy Number Gains of CCND1 Gene: A Study of 3 Cases With Nonmediastinal Disease. *The American Journal of Surgical Pathology*. 2019; 43(1):110-120.
8. Wagener R, Lopez C, Kleinheinz K, Bausinger J, Aukema SM, Nagel I, Toprak UH, Seufert J, Altmüller J, Thiele H, Schneider C, Kolarova J, Park J, Hubschmann D, Murga Penas EM, Drexler HG, Attarbaschi A, Hovland R, Kjeldsen E, Kneba M, Kontny U, **de Leval L**, Nurnberg P, Oschlies I, Oscier D, Schlegelberger B, Stilgenbauer S, Wossmann W, Schlesner M, Burkhardt B, Klapper W, Jaffe ES, Kuppers R, Siebert R. IG-MYC (+) neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas. *Blood*. 2018; 132(21):2280-2285.
9. Muller Brochut AC, Taffe P, Piaget-Rossel R, **de Leval L**, Rougemont AL. Fetal Anthropometric Features: A Postmortem Study of Fetuses After the Termination of Pregnancy for Psychosocial Reasons Between 12 and 20 Gestational Weeks. *Pediatric and Developmental Pathology*. 2019; 22(3):243-251.
10. Martin-Garcia D, Navarro A, Valdes-Mas R, Clot G, Gutierrez-Abril J, Prieto M, Ribera-Cortada I, Woroniecka R, Rymkiewicz G, Bens S, **de Leval L**, Rosenwald A, Ferry JA, Hsi ED, Fu K, Delabie J, Weisenburger D, de Jong D, Climent F, O'Connor SJ, Swerdlow SH, Torrents D, Beltran S, Espinet B, Gonzalez-Farre B, Veloza L, Costa D, Matutes E, Siebert R, Ott G, Quintanilla-Martinez L, Jaffe ES, Lopez-Otin C, Salaverria I, Puente XS, Campo E, Bea S. CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1(-) mantle cell lymphoma. *Blood*. 2019; 133(9):940-951.

11. Sciarra A, Monteiro I, Menetrier-Caux C, Caux C, Gilbert B, Halkic N, La Rosa S, Romero P, Sempoux C, **de Leval L**. CD73 expression in normal and pathological human hepatobiliopancreatic tissues. *Cancer Immunology, Immunotherapy* 2019; 68(3):467-478.
Correction to: CD73 expression in normal and pathological human hepatobiliopancreatic tissues. *Cancer Immunology, Immunotherapy*. 2019; 68(3):529.
12. Nguyen HT, Migliozi D, Bisig B, **de Leval L**, Gijs MAM. High-content, cell-by-cell assessment of HER2 overexpression and amplification: a tool for intratumoral heterogeneity detection in breast cancer. *Laboratory Investigation*. 2019; 99(5):722-732.
13. Heavican TB, Bouska A, Yu J, Lone W, Amador C, Gong Q, Zhang W, Li Y, Dave BJ, Nairismagi ML, Greiner TC, Vose J, Weisenburger DD, Lachel C, Wang C, Fu K, Stevens JM, Lim ST, Ong CK, Gascoyne RD, Missiaglia E, Lemonnier F, Haioun C, Hartmann S, Pedersen MB, Laginestra MA, Wilcox RA, Teh BT, Yoshida N, Ohshima K, Seto M, Rosenwald A, Ott G, Campo E, Rimsza LM, Jaffe ES, Braziel RM, d'Amore F, Inghirami G, Bertoni F, **de Leval L**, Gaulard P, Staudt LM, McKeithan TW, Pileri S, Chan WC, Iqbal J. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. *Blood*. 2019; 133(15):1664-1676.
14. Crickx E, Poullot E, Moulis G, Goulabchand R, Fieschi C, Galicier L, Meignin V, Coppo P, Delarue R, Casasnovas O, Roos-Weil D, **de Leval L**, Parrens M, Michel M, Dupuis J, Le Bras F, Fataccioli V, Martin-Garcia N, Godeau B, Haioun C, Gaulard P, Mahevas M. Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma. *European Journal of Haematology*. 2019; 103(1):35-42.
15. Jreige M, Letovanec I, Chaba K, Renaud S, Rusakiewicz S, Cristina V, Peters S, Krueger T, **de Leval L**, Kandalaft LE, Nicod-Lalonde M, Romero P, Prior JO, Coukos G, Schaefer N. ¹⁸F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer. *European Journal of Nuclear Medicine and Molecular Imaging*. 2019; 46 (9):1859-1868.
16. Aimi F, Procopio MG, Alvarez Flores MT, Brouland JP, Piazzon N, Brajkovic S, Dupouy DG, Gijs M, **de Leval L**. Microfluidic-based immunohistochemistry for breast cancer diagnosis: a comparative clinical study. *Virchows Archiv*. 2019; 475(3):313-323.
17. Banga R, Rebecchini C, Procopio FA, Noto A, Munoz O, Ioannidou K, Fenwick C, Ohmiti K, Cavassini M, Corpataux JM, **de Leval L**, Pantaleo G, Perreau M. Lymph node migratory dendritic cells modulate HIV-1 transcription through PD-1 engagement. *PLoS Pathogens*. 2019; 15 (7): e1007918.
18. Amador C, Greiner TC, Heavican TB, Smith LM, Galvis KT, Lone W, Bouska A, D'Amore F, Pedersen MB, Pileri S, Agostinelli C, Feldman AL, Rosenwald A, Ott G, Mottok A, Savage KJ, **de Leval L**, Gaulard P, Lim ST, Ong CK, Ondrejka SL, Song J, Campo E, Jaffe ES, Staudt LM, Rimsza LM, Vose J, Weisenburger DD, Chan WC, Iqbal J. Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. *Blood*. 2019; 134(24):2159-70.
19. Thurner L, Hartmann S, Fadle N, Regitz E, Kemele M, Kim YJ, Bohle RM, Nimmesgern A, von Müller L, Kempf VAJ, Weniger MA, Neumann F, Schneider N, Vornanen M, Sundström C, **de Leval L**, Engert A, Eichenauer DA, Küppers R, Preuss KD, Hansmann ML, Pfreundschuh M. Lymphocyte predominant cells detect *Moraxella catarrhalis*-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma. *Nature Communications*. 2020; 11(1): 2465.
20. Drieux F, Ruminy P, Abdel-Sater A, Lemonnier F, Viailly PJ, Fataccioli V, Marchand V, Bisig B, Letourneau A, Parrens M, Bossard C, Bruneau J, Dobay P, Veresezan L, Dupuy A, Pujals A, Robe C, Sako N, Copie-Bergman C, Delfau-Larue MH, Picquenot JM, Tilly H, Delarue R, Jardin F, **de Leval L**, Gaulard P. Defining signatures of peripheral T-cell lymphoma with a targeted 20-marker gene expression profiling assay. *Haematologica*. 2020; 105(6):1582-1592.
21. Soderquist CR, Patel N, Murty VV, Betman S, Aggarwal N, Young KH, Xerri L, Leeman-Neill R, Lewis SK, Green PH, Hsiao S, Mansukhani MM, Hsi ED, **de Leval L**, Alobeid B, Bhagat G. Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract. *Haematologica* 2020; 105(7), 1895–1906.

22. Özdemir BC, Latifyan S, Perreau M, Fenwick C, Alberio L, Waeber G, Spertini F, **de Leval L**, Michielin O, Obeid M. Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis. *Annals of Oncology*. 2020; 31(12):1775-1778.
23. Isidori A, **de Leval L**, Gergis U, Musto P, Porcu P. Management of Patients With Hematologic Malignancies During the COVID-19 Pandemic: Practical considerations and lessons to be learned. *Frontiers in Oncology*. 2020; 10:1439.
24. Tomita S, Kikuti YY, Carreras J, Sakai R, Takata K, Yoshino T, Bea S, Campo E, Missiaglia E, Bouilly J, Letourneau A, **de Leval L**, Nakamura N. Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma in Asia frequently shows SETD2 alterations. *Cancers*. 2020; 12(12):3539.
25. Tratwal J, Bekri D, Boussema C, Sarkis R, Kunz N, Koliqi T, Rojas-Sutterlin S, Schyrr F, Tavakol DN, Campos V, Scheller EL, Sarro R, Bárcena C, Bisig B, Nardi V, **de Leval L**, Burri O, Naveiras O. MarrowQuant Across Aging and Aplasia: A Digital Pathology Workflow for Quantification of Bone Marrow Compartments in Histological Sections. *Frontiers in Endocrinology*. 2020; 11:480.
26. Hofman P, Ilié M, Chamorey E, Brest P, Schiappa R, Nakache V, Antoine M, Barberis M, Begueret H, Bibeau F, Bonnetaud C, Boström P, Brousset P, Bubendorf L, Carvalho L, Cathomas G, Cazes A, Chalabreysse L, Chenard MP, Copin MC, Côté JF, Damotte D, **de Leval L**, Delongova P, Thomas de Montpreville V, de Muret A, Dema A, Dietmaier W, Evert M, Fabre A, Forest F, Foulet A, Garcia S, Garcia-Martos M, Gibault L, Gorkiewicz G, Jonigk D, Gosney J, Hofman A, Kern I, Kerr K, Kossai M, Kriegsmann M, Lassalle S, Long-Mira E, Lupo A, Mamilos A, Matěj R, Meilleroux J, Ortiz-Villalón C, Panico L, Panizo A, Papotti M, Pauwels P, Pelosi G, Penault-Llorca F, Pop O, Poté N, Cajal S, Sabourin JC, Salmon I, Sajin M, Savic-Prince S, Schildhaus HU, Schirmacher P, Serre I, Shaw E, Sizaret D, Stenzinger A, Stojic J, Thunnissen E, Timens W, Troncone G, Werlein C, Wolff H, Berthet JP, Benzaquen J, Marquette CH, Hofman V, Calabrese F. Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future. *ESMO open*. 2021; 6(1):100024.
27. Ioannidou K, Ndiaye DR, Noto A, Fenwick C, Fortis SP, Pantaleo G, Petrovas C, **de Leval L**. In Situ Characterization of Follicular Helper CD4 T Cells Using Multiplexed Imaging. *Frontiers in Immunology*. 2021; 11: 607626.
28. Lemonnier F, Safar V, Beldi-Ferchiou A, Cottureau AS, Bachy E, Cartron G, Fataccioli V, Pelletier L, Robe C, Letourneau A, Missiaglia E, Fourati S, Moles-Moreau MP, Delmer A, Bouabdallah R, Voillat L, Becker S, Bossard C, Parrens M, Casasnovas O, Cacheux V, Régnier C, Camus V, Delfau-Larue MH, Meignan M, **de Leval L**, Gaulard P, Haioun C. Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. *Blood Advances*. 2021; 5(2):539-548.
29. Schmitz N, Truemper LH, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, Jaccard A, Reimer P, Wagner-Drouet EM, Wilhelm M, Sanhes L, Lamy T, **de Leval L**, Rosenwald A, Roussel M, Kroschinsky FP, Lindemann WW, Dreger P, Viardot A, Milpied NJ, Gisselbrecht C, Wulf GG, Gyan E, Gaulard P, Bay JO, Glass B, Poeschel V, Damaj G, Sibon D, Delmer AJ, Bilger K, Banos A, Haenel M, Dreyling M, Metzner B, Keller U, Brulke F, Friedrichs B, Nickelsen M, Altmann B, Tournilhac O. A randomized phase 3 trial of auto vs allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL. *Blood*. 2021; 137(19):2646-2656.
30. Cachot A, Bilous M, Liu YC, Li X, Saillard M, Cenerenti M, Rockinger GA, Wyss T, Guillaume P, Schmidt J, Genolet R, Ercolano G, Protti MP, Reith W, Ioannidou K, **de Leval L**, Trapani JA, Coukos G, Harari A, Speiser DE, Mathis A, Gfeller D, Altug H, Romero P, Jandus C. Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. *Science Advances*. 2021; 7(9):eabe3348.
31. Monteiro I, Missiaglia E, Sciarra A, Santos JV, Bouilly J, Romero P, Sempoux C, **de Leval L**. CD73 expression in normal, hyperplastic, and neoplastic thyroid: a systematic evaluation revealing CD73 overexpression as a feature of papillary carcinomas. *Virchows Archiv*. 2021; 479 (1):209-214.
32. Carras S, Chartoire D, Mareschal S, Heiblig M, Marçais A, Robinot R, Urb M, Pommier RM, Julia E, Chebel A, Verney A, Bertheau C, Bardel E, Fezelot C, Courtois L, Lours C, Bouska A, Sharma S, Lefebvre C, Rouault JP, Sibon D, Ferrari A, Iqbal J, **de Leval L**, Gaulard P, Traverse-Glehen A, Sujobert P, Blery M, Salles G, Walzer T, Bachy E, Genestier L., Chronic T cell receptor stimulation

unmasks NK receptor signaling in peripheral T cell lymphomas via epigenetic reprogramming. *Journal of Clinical Investigation* 2021; 131(13):e139675.

33. Elgaafary S, López C, Nagel I, Vater I, Bens S, Szczepanowski M, Aukema SM, Wagener R, Hopp L, Binder H, **de Leval L**, Klapper W, Siebert R. Molecular characterization of Burkitt lymphoma in the breast or ovary. *Leukemia & Lymphoma*. 2021; 62(9), 2120–2129.
34. Drieux F, Ruminy P, Sater V, Marchand V, Fataccioli ., Lanic MD, Viennot M, Viailly .J, Sako N, Robe C, Dupuy A, Vallois D, Veresezan L, Poullot E, Picquenot JM, Bossard C, Parrens M, Lemonnier F, Jardin F, **de Leval L**, Gaulard P, Detection of Gene Fusion Transcripts in Peripheral T-Cell Lymphoma Using a Multiplexed Targeted Sequencing Assay. *The Journal of Molecular Diagnostics*. 2021; 23(8):929-940.
35. Debackere K., Marcelis L., Demeyer S., Vanden Bempt M., Mentens N., Gielen O, Jacobs K., Broux M, Verhoef G, Michaux L, Graux C, Wlodarska I, Gaulard P, **de Leval L**, Tousseyn T, Cools J, Dierickx D. Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified. *Nature Communications*. 2021; 12(1): 3705.
36. Berezowska S, Lefort K., Ioannidou K, Ndiaye DR, Maison D, Petrovas C, Rotman S, Piazzon N, Milowich D, Sala N, Tsai CY, Multone E, Bochud PY, Oddo M, Bisig ., **de Leval L**. Postmortem Cardiopulmonary Pathology in Patients with COVID-19 Infection: Single-Center Report of 12 Autopsies from Lausanne, Switzerland. *Diagnostics*. 2021; 11(8):1357.
37. Merli AM, Vieujean S, Massot C, Blétard N, Quesada Calvo F, Baiwir D, Mazzucchelli G, Servais L, Wéra O, Oury C, **de Leval L**, Sempoux C, Manzini R, Bluemel S, Scharl M, Rogler G, De Pauw E, Coimbra Marques C, Colard A, Vijverman A, Delvenne P, Louis E, Meuwis MA. Solute carrier family 12 member 2 as a proteomic and histological biomarker of dysplasia and neoplasia in ulcerative colitis. *Journal of Crohn's & Colitis*. 2021; 15(2):287–298.
38. Liang HC, Costanza M, Prutsch N, Zimmerman MW, Gurnhofer E, Montes-Mojarro IA, Abraham BJ, Prokoph N, Stoiber S, Tangermann S, Lobello C, Oppelt J, Anagnostopoulos I, Hielscher T, Pervez S, Klapper W, Zammarchi F, Silva DA, Garcia KC, Baker D, Janz M, Schleussner N, Fend F, Pospíšilová Š, Janiková A, Wallwitz J, Stoiber D, Simonitsch-Klupp I, Cerroni L, Pileri S, **de Leval L**, Sibon D, Fataccioli V, Gaulard P, Assaf C, Knörr F, Damm-Welk C, Woessmann W, Turner SD, Look AT, Mathas S, Kenner L, Merkel O. Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma. *Nature Communications* 2021;12(1):5577.
39. Wu W, Nelson G, Koch R, Donovan KA, Nowak RP, Heavican-Foral TB, Nirmal AJ, Liu H, Yang L, Duffy J, Powers F, Stevenson KE, Jones M, Ng SY, Wu G, Jain S, Xu R, Amaka S, Trevisani C, Donaldson N, Hagner PR, **de Leval L**, Gaulard P, Iqbal J, Thakurta A, Fischer ES, Adelman K, Weinstock DM. Overcoming IMiD Resistance in T-cell Lymphomas Through Potent Degradation of ZFP91 and IKZF1. *Blood*. 2021; 139(13):2024-2037.
40. Bonfiglio F, Bruscazzin A, Guidetti F, Terzi di Bergamo L, Faderl MR, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Piroso MC, Cittone MG, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista MJ, Bastidas G, Beà S, Boldorini R, Broccoli A, Bühler MM, Canzonieri V, Cascione L, Ceriani L, Cogliatti SB, Corradini P, Derenzini E, Devizzi L, Dietrich S, Elia AR, Facchetti F, Gaidano G, Garcia JF, Gerber B, Ghia P, Gomes da Silva M, Gritti G, Guidetti A, Hitz F, Inghirami GG, Ladetto M, López-Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia AA, Mollejo M, Montalban C, Novak U, Oscier DG, Passamonti F, Piazza FA, Pizzolitto S, Rambaldi A, Sabattini E, Salles GA, Santambrogio E, Scarfo L, Stathis A, Stussi G, Geyer JT, Tapia G, Tarella C, Thieblemont C, Tousseyn T, Tucci A, Vanini G, Visco C, Vitolo U, Walewska R, Zaja F, Zenz T, Zinzani PL, Khiabani H, Calcinotto A, Bertoni F, Bhagat G, Campo E, **de Leval L**, Dirnhofer S, Pileri SA, Piris MA, Traverse-Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D Genetic and phenotypic attributes of splenic marginal zone lymphoma. *Blood*. 2022; 139(5):732-747.
41. Fortarezza F, Pezzuto F, Hofman P, Kern I, Panizo A, von der Thüsen J, Timofeev S, Gorkiewicz G, Berezowska S, **de Leval L**, Ortiz-Villalón C, Lunardi F, Calabrese F. COVID-19 Pulmonary Pathology: The Experience of European Pulmonary Pathologists throughout the First Two Waves of the Pandemic. *Diagnostics (Basel)*. 2022; 12(1):95.

42. Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas RO, Ysebaert L, Damaj G, Guidez S, Pica GM, Kim WS, Lim ST, André M, García-Sancho AM, Penarrubia MJ, Staber PB, Trotman J, Hüttmann A, Stefoni V, Re A, Gaulard P, Delfau-Larue MH, **de Leval L**, Meignan M, Li J, Morschhauser F, Delarue R. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). *Journal of Clinical Oncology*. 2022; 40(3):242-251.
43. Domizio JD, Gulen MF, Saidoune F, Thacker VV, Yatim A, Sharma K, Nass T, Guenova E, Schaller M, Conrad C, Goepfert C, **de Leval L**, Garnier CV, Berezowska S, Dubois A, Gilliet M, Ablasser A. The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. *Nature*. 2022; 603(7899):145-151.
44. Dreyling M, André M, Gökbüget N, Tilly H, Jerkeman M, Gribben J, Ferreri A, Morel P, Stilgenbauer S, Fox C, Ribera JM, Zweegman S, Aurer I, Bodor C, Burkhardt B, Buske C, Caballero MD, Campo E, Chapuy B, Davies A, **de Leval L**, Doorduijn J, Federico M, Gaulard P, Gay F, Ghia P, Groenbaek K, Goldschmidt H, Kersten MJ, Kiesewetter B, Landman-Parker J, LeGouill S, Lenz G, Leppä S, Lopez-Guillermo A, MacIntyre E, Mateos Mantega MV, Moreau P, Moreno C, Nadel B, Okosun J, Owen R, Pospisilova S, Pott C, Robak T, Spina M, Stamatopoulos K, Stary J, Tarte K, Tedeschi A, Thieblemont C, Trappe RU, Trümper L, Salles G. The EHA research roadmap: Malignant Lymphoid Diseases. *HemaSphere*. 2022; 19;6(6):e726.
45. Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, **de Leval L**, Dirnhofer S, Dogan A, Feldman A, Fend F, Friedberg JW, Gaulard P, Ghia P, Horwitz SM, King RL, Salles GA, San-Miguel JF, Seymour JF, Treon SP, Vose J, Zucca E, Advani R, Ansell SM, Au WY, Barrionuevo C, Bergsagel PL, Chan WC, Cohen JI, d'Amore F, Davies AJ, Falini B, Ghobrial IM, Goodlad JR, Gribben JG, Hsi ED, Kahl BS, Kim WS, Kumar SK, LaCasce AS, Laurent C, Lenz G, Leonard JP, Link MP, López-Guillermo A, Mateos MV, Macintyre EA, Melnick AM, Morschhauser F, Nakamura S, Narbaitz M, Pavlovsky A, Pileri SA, Piris MA, Pro B, Rajkumar SVV, Rosen ST, Sander B, Sehn LH, Shipp MA, Smith SM, Staudt LM, Thieblemont C, Tousseyn T, Wilson WH, Yoshino T, Zinzani PL, Dreyling M, Scott DW, Winter JN, Zelenetz AD. The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. *Blood*. 2022; 140(11), 1229-1253. *Blood*. 2023; 141(4), 437.
46. Evangelou K, Veroutis D, Paschalaki K, Foukas PG, Lagopati N, Dimitriou M, Paspaspyropoulos A, Konda B, Hazapis O, Polyzou A, Havaki S, Kotsinas A, Kittas C, Tzioufas AG, **de Leval L**, Vassilakos D, Tsiodras S, Stripp BR, Papantonis A, Blandino G, Karakasiliotis I, Barnes PJ, Gorgoulis VG. Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis. *The European Respiratory Journal*. 2022; vol. 60,2 2102951.
47. Nicolae A, Bouilly J, Lara D, Fataccioli V, Lemonnier F, Drieux F, Parrens M, Robe C, Poullot E, Bisig B, Bossard C, Letourneau A, Missiaglia E, Bonnet C, Szablewski V, Traverse-Glehen A, Delfau-Larue MH, **de Leval L**, Gaulard P. Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations. *Modern Pathology*. 2022; 35(8):1126-1136.
48. **de Leval L**, Alizadeh AA, Bergsagel PL, Campo E, Davies AJ, Dogan A, Fitzgibbon J, Horwitz SM, Melnick AM, Morice WG, Morin RD, Nadel B, Pileri SA, Rosenquist R, Rossi D, Salaverria I, Steidl C, Treon SP, Zelenetz AD, Advani R, Allen CE, Ansell SM, Chan WC, Cook JR, Cook LB, d'Amore F, Dirnhofer S, Dreyling M, Dunleavy K, Feldman A, Fend F, Gaulard P, Ghia P, Gribben JG, Hermine O, Hodson DJ, Hsi ED, Inghirami GG, Jaffe ES, Karube K, Kataoka K, Klapper W, Kim WS, King RL, Ko YH, LaCasce AS, Lenz G, Martin-Subero I, Piris MA, Pittaluga S, Pasqualucci L, Quintanilla-Martinez L, Rodig SJ, Rosenwald A, Salles GA, San-Miguel J, Savage KJ, Sehn LH, Semenzato G, Staudt LM, Swerdlow SH, Tam CS, Trotman J, Vose J, Weigert O, Wilson WH, Winter JN, Wu CJ, Zinzani PL, Zucca E, Bagg A, Scott DWW. Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms. *Blood* 2022; 140(21), 2193-2227.
49. Sarkis R, Burri O, Royer-Chardon C, Schyrr F, Blum S, Costanza M, Cherix S, Piazzon N, Barcena C, Bisig B, Nardi V, Sarro R, Ambrosini G, Weigert M, Spertini O, Blum S, Deplancke B, Seitz A, **de Leval L**, Naveiras O. MarrowQuant 2.0: A Digital Pathology Workflow Assisting Bone Marrow Evaluation in Experimental and Clinical Hematology. *Modern Pathology*. 2023; 36(4), 100088.

50. Leca J, Lemonnier F, Meydan C, Foox J, El Ghamrasni S, Mboumba DL, Duncan GS, Fortin J, Sakamoto T, Tobin C, Hodgson K, Haight J, Smith LK, Elia AJ, Butler D, Berger T, **de Leval L**, Mason CE, Melnick A, Gaulard P, Mak TW. IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment. *Cancer Cell*. 2023; 41(2), 323–339.e10.
51. Veloza L, Cavalieri D, Missiaglia E, Ledoux-Pilon A, Bisig B, Pereira B, Bonnet C, Poullot E, Quintanilla-Martinez L, Dubois R, Llamas-Gutierrez F, Bossard C, De Wind R, Drieux F, Fontaine J, Parrens M, Sandrini J, Fataccioli V, Delfau-Larue MH, Daniel A, Lhomme F, Clément-Filliatre L, Lemonnier F, Cairoli A, Morel P, Glaisner S, Joly B, El Yamani A, Laribi K, Bachy E, Siebert R, Vallois D, Gaulard P, Tournilhac O, **de Leval L**. Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome. *Haematologica*. 2023; 108(1):181-195.
52. Sesboue C, Galtier J, Jeanneau M, Chauvel A, Laharanne E, Amintas S, Merlio JP, Bouabdallah K, Gros FX, **de Leval L**, Gros A, Parrens M. Combined Reverse-Transcriptase Multiplex Ligation-Dependent Probe Amplification and Next-Generation Sequencing Analyses to Assign Unclassified BCL2-/BCL6- Nonrearranged Small B-Cell Lymphoid Neoplasms as Follicular or Nodal Marginal Zone Lymphoma. *Modern Pathology*. 2023; 36(2):100043.
53. Decroos A, Cheminant M, Bruneau J, Carras S, Parinet V, Pelletier L, Lacroix L, Martin N, Giustiniani J, Lhermitte L, Asnafi V, Battistella M, Lemonnier F, **de Leval L**, Sicard H, Bonnafeous C, Gauthier L, Genestier L, Caruso S, Gaulard P, Hermine O, Ortonne N. KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma. *Haematologica*. 2023; 108(10):2830-2836
54. Sibon D, Bisig B, Bonnet C, Poullot E, Bachy E, Cavalieri D, Fataccioli V, Bregnard C, Drieux F, Bruneau J, Lemonnier F, Dupuy A, Bossard C, Parrens M, Bouabdallah K, Ketterer N, Berthod G, Cairoli A, Damaj G, Tournilhac O, Jais JP, Gaulard P, **de Leval L**. ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics, but not better overall survival: a LYSA study. *Haematologica*. 2023;108(6):1590-1603.
55. Thurner L, Fadle N, Regitz E, Roth S, Cetin O, Kos IA, Hess SM, Bein J, Bohle RM, Vornanen M, Sundström C, **de Leval L**, Tiacci E, Borchmann P, Engert A, Poeschel V, Held G, Schwarz EC, Neumann F, Preuss KD, Hoth M, Küppers R, Lehman K, Hansmann ML, Becker SL, Bewarder M, Hartmann S. B-cell receptor reactivity against *Rothia mucilaginosa* in nodular lymphocyte-predominant Hodgkin lymphoma. *Haematologica*. 2023;108(12):3347-3358.
56. Oyler BL, Valencia-Dávila JA, Moysi E, Molyvdas A, Ioannidou K, March K, Ambrozak D, **de Leval L**, Fabozzi G, Woods AS, Koup RA, Petrovas C. Multilevel human secondary lymphoid immune system compartmentalization revealed by complementary imaging approaches. *iScience*. 2023; 26(8):107261.
57. Papadopoulou V, Barcena-Garcia C, Basset V, Schoumans J, **de Leval L**, Schaller M. Invariant finding of non-clonal bone marrow lymphocytosis, with increased B cell component, in indolent systemic mastocytosis. *International Journal of Laboratory Hematology*. 2023; 45(6):1007-1010.
58. Joo V, Petrovas C, **de Leval L**, Noto A, Obeid M, Fenwick C, Pantaleo G. A CD64/FcγRI-Mediated Mechanism Hijacks PD-1 from PD-L1/2 Interaction and Enhances Anti-PD-1 Functional Recovery of Exhausted T cells. *Frontiers in Immunology*. 2023; 14:1213375.
59. Hofman P, Calabrese F, Kern I, Adam J, Alarcão A, Alborelli I, Anton NT, Arndt A, Avdalyan A, Barberis M, Bégueret H, Bisig B, Blons H, Boström P, Brcic L, Bubanovic G, Buisson A, Caliò A, Cannone M, Carvalho L, Caumont C, Cayre A, Chalabreysse L, Chenard MP, Conde E, Copin MC, Côté JF, D'Haene N, Dai HY, **de Leval L**, Delongova P, Denčić-Fekete M, Fabre A, Ferenc F, Forest F, de Fraipont F, Garcia-Martos M, Gauchotte G, Geraghty R, Guerin E, Guerrero D, Hernandez S, Hurník P, Jean-Jacques B, Kashofer K, Kazdal D, Lantuejoul S, Leonce C, Lupo A, Malapelle U, Matej R, Merlin JL, Mertz KD, Morel A, Mutka A, Normanno N, Ovidiu P, Panizo A, Papotti MG, Parobkova E, Pasello G, Pauwels P, Pelosi G, Penault-Llorca F, Picot T, Piton N, Pittaro A, Planchard G, Poté N, Radonic T, Rapa I, Rappa A, Roma C, Rot M, Sabourin JC, Salmon I, Prince SS, Scarpa A, Schuurin E, Serre I, Siozopoulou V, Sizaret D, Smojver-Ježek S, Solassol J, Steinestel K, Stojšić J, Strykh C,

- Timofeev S, Tronccone G, Uguen A, Valmary-Degano S, Vigier A, Volante M, Wahl SGF, Stenzinger A, Ilié M. Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe. *ESMO Open*. 2023; 8(5):101628.
60. Straub M, Auderset A, **de Leval L**, Piazzon N, Maison D, Vozenin MC, Ollivier J, Petit B, Sigman DM, Martínez-García A. Nitrogen isotopic composition as a gauge of tumor cell anabolism-to-catabolism ratio. *Scientific reports*. 2023; 13(1):19796.
 61. Pouillot E, Milowich D, Lemonnier F, Bisig B, Robe C, Pelletier L, Letourneau A, Dupuy A, Sako N, Ketterer N, Carde P, Dartigues P, Delfau-Larue MH, **de Leval L**, Gaulard P. Angioimmunoblastic T-cell lymphoma and Kaposi sarcoma: A fortuitous collision? *Histopathology*. 2024; 84(3):556-564.
 62. Sarro R, Bisig B, Guey B, Missiaglia E, Cairoli A, Omoumi P, Letovanec I, Ferry JA, Hasserjian RP, **de Leval L**. Follicular lymphoma presenting with symptomatic bone involvement: a clinicopathological and molecular analysis of 16 cases. *Modern pathology*. 2024; 37(4):100440.
 63. Camus V, Thieblemont C, Gaulard P, Cheminant M, Casasnovas RO, Ysebaert L, Damaj GL, Guidez S, Pica GM, Kim WS, Lim ST, Andre M, Gutiérrez N, Penarrubia MJ, Staber PB, Trotman J, Hüttmann A, Stefoni V, Tucci A, Fogarty P, Farhat H, Abraham J, Abarah W, Belmecheri F, Ribrag V, Delfau-Larue MH, Cottreau AS, Itti E, Li J, Delarue R, **de Leval L**, Morschhauser F, Bachy E. Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial. *Journal of Clinical Oncology*. 2024; 42(14):1612-1618.
 64. Chmiest D, Podavini S, Vallois D, Ioannidou K, Decaillet C, Gonzalez M, Quadroni M, Blackney K, Schairer R, **de Leval L**, Thome M. PD1 inhibits PKC θ -dependent phosphorylation of cytoskeleton-related proteins and immune synapse formation. *Blood Advances*. 2024; 8(11):2908-2923.
 65. Dupuis J, Bachy E, Morschhauser F, Cartron G, Fukuhara N, Daguindau N, Casasnovas RO, Snauwaert S, Gressin R, Fox CP, d'Amore FA, Staber PB, Tournilhac O, Bouabdallah K, Thieblemont C, André M, Rai S, Ennishi D, Gkasiamis A, Nishio M, Fornecker LM, Delfau-Larue MH, Sako N, Mule S, **de Leval L**, Gaulard P, Tsukasaki K, Lemonnier F. Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study. *The Lancet Haematology*. 2024; 11(6):e406-e414.
 66. Yuta Ito Y, Marouf A, Kogure Y, Koya J, Liévin R, Bruneau J, Tabata M, Saito Y, Shingaki S, Yuasa M, Yamaguchi K, Murakami K, Weil R, Vavasseur M, Andrieu G, Latiri M, Veleanu L, Dussiot M, André I, Joshi A, Lagresle-Peyrou C, Magerus A, Chaubard S, Lavergne D, Bachy E, Brunet E, Fataccioli V, Brouzes C, Laurent C, **de Leval L**, Traverse-Glehen A, Bossard C, Parrens MC, Meignin V, Philippe L, Rossignol J, Suarez F, Jean-Marie Michot JM, Tournilhac O, Damaj G, Lemonnier F, Bole C, Nitschké P, Tesson B, Laurent C, Molina T, Asnafi V, Watatani Y, Chiba K, Okada A, Shiraishi Y, S, Izutsu K, Miyoshi H, Ohshima K, Sakata S, Dobashi A, Takeuchi K, Sanada M, Gaulard P, Jaccard A, Ogawa S, Hermine O, Kataoka K, Couronné L. Comprehensive genetic profiling reveals frequent alterations of driver genes on the X chromosome in extranodal NK/T-cell lymphoma. *Cancer Research*. 2024; 84(13), 2181–2201.
 67. Stephan P, Perrot J, Voisin A, Barbery M, Andrieu T, Grimont M, Caramel J, Bardou M, Tondeur G, Missiaglia E, Gaulard P, Lemonnier F, **de Leval L**, Bachy E, Sujobert P, Genestier L, Traverse-Glehen A, Grinberg-Bleyer Y. Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets. *Haematologica*. 2025; 110(1):129-141.
 68. Sobottka B, Vetter V, Banaei-Esfahani A, Nowak M, Lorch A, Sirek A, Mertz KD, Brunelli M, Berthold D, **de Leval L**, Kahraman A, Koelzer VH, Moch H. Immune phenotype-genotype associations in primary clear cell renal cell carcinoma and matched metastatic tissue. *Modern Pathology*. 2024; 37(10), 100558.
 69. Chantziou A, Brenna C, Ioannidou K, Chen OY, Korkolopoulou PA, Antoniadou A, Psychogiou M, Papaioannou M, Tsigiotis P, Foukas P, **de Leval L**, Petrovas C. HIV infection is associated with compromised tumor microenvironment adaptive immune reactivity in Hodgkin Lymphoma. *Blood Advances*. 2024; 8(24):6215-6231.

70. **de Leval L**, Gaulard P, Dogan A. A practical approach to the modern diagnosis and classification of T-and NK-cell lymphomas. *Blood*. 2024; 144(18):1855-1872.
71. Schyrr F, Alonso-Calleja A, Vijaykumar A, Sordet-Dessimoz J, Gebhard S, Sarkis R, Bataclan C, Lopes S, Oggier A, **de Leval L**, Nombela-Arrieta C, Naveiras O. Inducible CXCL12/CXCR4-dependent extramedullary hematopoietic niches in the adrenal gland. *Blood*. 2024; 144(9):964-976.
72. Moysi E, Sharma AA, O'Dell S, Georgakis S, Del Rio Estrada PM, Torres-Ruiz F, Navarro MG, Villalobos YAL, Rios SA, Reyes-Teran G, Beddall MH, Ko SH, Belinky F, Orfanakis M, **de Leval L**, Enriquez AB, Buckner CM, Moir S, Doria-Rose N, Boritz E, Mascola JR, Sekaly RP, Koup RA, Petrovas C. Neutralization activity in chronic HIV infection is characterized by a distinct programming of follicular helper CD4 T cells. 2024; 2024.07.31.605954. *Preprint*.
73. Tournilhac O, Altmann B, Friedrichs B, Bouabdallah K, Leclerc M, Cartron G, Turlure P, Reimer P, Wagner-Drouet E, Sanhes L, Houot R, Roussel M, Kroschinsky F, Dreger P, Viardot A, **de Leval L**, Rosenwald A, Gaulard P, Wulf G, Villate A, Latiere C, Elmaagacli A, Glass B, Poeschel V, Damaj G, Sibon D, Durot E, Bilger K, Banos A, Haenel M, Dreyling M, Keller U, Tiab M, Drenou B, Cornillon J, Nguyen S, Robin M, Nickelsen M, Trümper L, Lenz G, Ziepert M, Schmitz N; French Lymphoma Study Association (LYSA), the Société Francophone de greffe de moelle et Thérapie Cellulaire (SFGM-TC), and the German Lymphoma Alliance (GLA). Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma). *Journal of clinical oncology*. 2024; 42(32), 3788–3794.
74. Özoğul E, Montaner A, Pol M, Frigola G, Balagué O, Strykh C, Bousquets-Muñoz P, Royo R, Fontaine J, Traverse-Glehen A, Bühler MM, Giudici L, Roncador M, Zenz T, Carras S, Valmary-Degano S, **de Leval L**, Bosch-Schips J, Climent F, Salmeron-Villalobos J, Bashiri M, Ruiz-Gaspà S, Costa D, Beà S, Salaverria I, Giné E, Quintanilla-Martinez L, Brousset P, Raffeld M, Jaffe ES, Puente XS, López C, Nadeu F, Campo E. Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma. *Blood cancer journal*. 2024; 14(1), 166.
75. Fischer A, Albert TK, Moreno N, Interlandi M, Mormann J, Glaser S, Patil P, de Faria FW, Richter M, Verma A, Balbach ST, Wagener R, Bens S, Dahlum S, Göbel C, Münter D, Inserte C, Graf M, Kremer E, Melcher V, Di Stefano G, Santi R, Chan A, Dogan A, Bush J, Hasselblatt M, Cheng S, Spetalen S, Fosså A, Hartmann W, Herbrüggen H, Robert S, Oyen F, Dugas M, Walter C, Sandmann S, Varghese J, Rossig C, Schüller U, Tzankov A, Pedersen MB, d'Amore FA, Mellgren K, Kontny U, Kancherla V, Veloza L, Missiaglia E, Fataccioli V, Gaulard P, Burkhardt B, Soehnlein O, Klapper W, **de Leval L**, Siebert R, Kerl K. Lack of SMARCB1 expression characterizes a subset of human and murine peripheral T-cell lymphomas. *Nature communications*. 2024; 15(1), 8571.
76. Koya J, Tanigawa T, Mizuno K, Kim H, Ito Y, Yuasa M, Yamaguchi K, Kogure Y, Saito Y, Shingaki S, Tabata M, Murakami K, Chiba K, Okada A, Shiraishi Y, Marouf A, Liévin R, Chaubard S, Jaccard A, Hermine O, **de Leval L**, Tournilhac O, Damaj G, Gaulard P, Couronné L, Yasui T, Nakashima K, Miyoshi H, Ohshima K, Kataoka K. Modeling NK-cell lymphoma in mice reveals its cell-of-origin and microenvironmental changes and identifies therapeutic targets. *Nature communications*. 2024; 15(1), 9106.

Letters, editorials and brief reports

1. Dargent JL, Tinton N, Trimech M, **de Leval L**. Lymph node involvement by enteropathy-like indolent NK-cell proliferation. *Virchows Archiv*. 2020; 478(6), 1197–1202.
2. **de Leval L**. Chromosomes in breast lymphoma. *Blood* 2020; 136(25):2848-2849.
3. Gengler C., Dubruc E., Favre G., Greub G., **de Leval L.**, Baud D. SARS-CoV-2 ACE-receptor detection in the placenta throughout pregnancy. *Clinical Microbiology and Infection* 2021; 27(3):489-490.
4. Voruz S, Blum S, **de Leval L**, Schoumans J, Solly F, Spertini O. Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript. *Biomarker Research*. 2021; 9(1):92.

5. Houot R, Poeschel V, Altmann B, Angel S, Thurner L, Illmer T, Andre M, Dreyling M, Maisonneuve H, Tilly H, Mayer S, Casasnovas O, Le Gouill S, Offner F, Cartron G, Kerkhoff A, Weber T, Hoffmann J, Ziepert M, Klapper W, Itti E, Hellwig D, Natchkebia G, de Leval L, Rosenwald A, Haioun C, Dercle L, Gaulard P, Held G. Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma. *HemaSphere*. 2022; 6(2):e672
6. Ségot A, Stalder G, **de Leval L**, Solly F, Schoumans J, Basset V, Blum S, Spertini O. Venetoclax combined with FLAG-based chemotherapy induces an early and deep response in mixed-phenotype-acute leukemia. *American Journal of Hematology*. 2022; 97(3):E91-E93.

Case reports

1. Rebecchini C, Trimech M, Rosselet A, **de Leval L**. Crystal-Storing Histiocytosis. *International Journal of Surgical Pathology* 2019; 27(4):399-400.
2. Haefliger S, Milowich D, Sciarra A, Trimech M, Bouilly J, Kaiser J, Volpi S, Brouland JP, Sempoux C, **de Leval L**. Primary hepatic marginal B cell lymphoma of mucosa-associated lymphoid tissue (MALT) and non-alcoholic steatohepatitis (NASH): more than a coincidence? *Annals of Hematology* 2019; 98(6):1513-6.
3. Christin A, **de Leval L**, Obeid M. A Diffuse Medullary Hypercaptation With No Bone Lesion. *JAMA Oncology* 2020; 6(2):291-292.
4. Othenin-Girard A, Regamey J, Lamoth F, Horisberger A, Glampedakis E, Epiney JB, Kuntzer T, **de Leval L**, Carballares M, Hurni CA, Rusca M, Pantet O, Di Bernardo S, Oddo M, Comte D, Piquilloud L. Multisystem inflammatory syndrome with refractory cardiogenic shock due to acute myocarditis and mononeuritis multiplex after SARS-CoV-2 infection in an adult. *Swiss Medical Weekly* 2020; 150: w20387.
5. Salvioni Chiabotti P, Bisig B, Cairoli A, Hajdu SD, Lovey PY, Milowich D, Ziadi S, Du Pasquier R, Brouland JP, **de Leval L**. Meningeal Relapse of Nodular Lymphocyte Predominant Hodgkin Lymphoma Transformed to T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Case Report. *Frontiers in Oncology* 2020; 10:1745.
6. Thurner L, Hartmann S, Fadle N, Regitz E, Kemele M, Kim YJ, Bohle RM, Nimmesgern A, von Müller L, Kempf V, Weniger MA, Neumann F, Schneider N, Vornanen M, Sundström C, **de Leval L**, Engert A, Eichenauer DA, Küppers R, Preuss KD, Hansmann ML, Pfreundschuh M. Lymphocyte predominant cells detect *Moraxella catarrhalis*-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma. *Nature Communications*. 2020; 11(1):2465.
7. Peeters M, Geusens J, Van der Cruyssen F, Michaux L, **de Leval L**, Tousseyn T, Vandenberghe P, Politis C. Spontaneous Remission of an Infraorbital Follicular B-Cell Lymphoma: Case Report and Review of the Literature. *Pathology Oncology Research* 2021; 27:642433.
8. Voruz S, **de Leval L**, Cairoli A, Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine. *Experimental Hematology & Oncology* 2021; 10(1):32.
9. Trimech M, Letourneau A, Missiaglia E, De Prijck B, Nagy-Hulliger M, Somja J, Vivario M, Gaulard P, Lambert F, Bisig B, de Leval L. Angioimmunoblastic T-Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Novel Form of Composite Lymphoma Potentially Mimicking Richter Syndrome. *The American Journal of Surgical Pathology*. 2021; 45(6):773-786.
10. Favre G, Mazzetti S, Gengler C, Bertelli C, Schneider J, Laubscher B, Capoccia R, Pakniyat F, Ben Jazia I, Eggel-Hort B, **de Leval L**, Pomar L, Greub G, Baud D, Giannoni E. Decreased Fetal Movements: A Sign of Placental SARS-CoV-2 Infection with Perinatal Brain Injury. *Viruses*. 2021; 13(12):2517.
11. Halfon M, Cochat P, Kissling S, Dattner N, **de Leval L**, Fakhouri F, Pruijm M, Bonny O. A stone in the bone. *JIMD Reports*. 2021; 62(1), 6-8.

12. Laribi K, Baugier de Materre A, Touileb Y, Boursot C, Sandrini J, Cavaliere D, Pastoret C, **de Leval L**, Tournilhac O. Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma. *Hemasphere*. 2022; 6(2):e675.
13. Veloza L, Tsai CY, Bisig B, Pantet O, Alberio L, Sempoux C, Cavassini M, **de Leval L**, EBV-positive large B-cell lymphoma with an unusual intravascular presentation and associated haemophagocytic syndrome in an HIV-positive patient: report of a case expanding the spectrum of EBV-positive immunodeficiency-associated lymphoproliferative disorders. *Virchows Archiv*. 2022; 480 (3), 699-705.
14. Janowczyk A, Baumhoer D, Dirnhofer S, Grobholz R, Kipar A, **de Leval L**, Merkler D, Michielin O, Moch H, Perren A, Rottenberg S, Rubbia-Brandt L, Rubin MA, Sempoux C, Tolnay M, Zlobec I, Koelzer VH; Swiss Digital Pathology Consortium (SDiPath). Towards a national strategy for digital pathology in Switzerland. *Virchows Archiv*. 2022; 481(4), 647-652.
15. Bisig B, Cairoli A, Gaide O, Somja J, Bregnard C, Gaulard P, Xerri L, Lefort K, Missiaglia E, Gilliet M, Hohl D, Guenova E, **de Leval L**. Cutaneous presentation of enteropathy-associated T-cell lymphoma masque-rading as a DUSP22-rearranged CD30+ lymphoproliferation. *Virchows Archiv*. 2022; 481(4), 653-657.
16. Christe L, Veloza L, Gros L, Bisig B, Blum S, Hewer E, **de Leval L**. HHV8-negative primary effusion-based large B-cell lymphoma in a patient with chronic myeloid leukemia, BCR::ABL1-positive under dasatinib treatment: report of a new case and literature review. *Diagnostic cytopathology*. 2022; 50(12):E351-E356.
17. Blanchard G, Bisig B, **de Leval L**, Hohl D, Guenova E. Cytokine-pathway blockers worsen mycosis fungoides masquerading as psoriasis. *JAAD Case Reports*. 2024; 48:98-102.
18. Loser V, Segot A, **de Leval L**, Bisig B, Brouland JP, Hewer E, Barcena C, Hottinger AF, Pot C. Primary diffuse large B-cell lymphoma of the central nervous system identified with CSF biomarkers. *BMC Neurology*. 2024; 24(1), 250.

Review Articles

1. **de Leval L**. New Data in the Molecular Pathology of T-cell Lymphomas. *Leading Opinions Hämatologie und Onkologie*. 2019; 15(5):43-45.
2. **de Leval L**. Approach to nodal-based T-cell lymphomas. *Pathology* 2020; 52(1):78-99.
3. **de Leval L**, Jaffe ES. Lymphoma Classification. *Cancer Journal* 2020; 26(3):176-185.
4. Bachy E, Broccoli A, Dearden C, **de Leval L**, Gaulard P, Koch R, Morschhauser F, Trümper L, Zinzani PL. Controversies in the Treatment of Peripheral T-cell Lymphoma. *HemaSphere* 2020; 4(5):e461.
5. Milowich D, **de Leval L**. An update on the pathology of extranodal T-cell lymphomas. *Diagnostic Histopathology* 2020; 26(9):379-387.
6. Foukas PG, Bisig B, **de Leval L**. Recent advances upper gastrointestinal lymphomas: molecular updates and diagnostic implications. *Histopathology* 2021; 78(1):187-214.
7. Bron D, **de Leval L**, Michiels S, Wittnebel S; EuroBloodNet for rare diseases. Hepatosplenic T-cell lymphoma: treatment challenges. *Current Opinion in Oncology* 2021; 33(5):406-411.
8. Kimura H, **de Leval L**, Cai Q, Kim W. EBV-associated NK and T-cell lymphoid neoplasms. *Current Opinion in Oncology*. 2022; 34(5), 422–431.
9. Zamò A, van den Brand M, Climent F, **de Leval L**, Dirnhofer S, Leoncini L, Ng SB, Ondrejka SL, Quintanilla-Martinez L, Soma L, Wotherspoon A. The many faces of nodal and splenic marginal zone lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop. *Virchows Archiv*. 2023; 483(3):317-331. Erratum in: *Virchows Archiv*. 2023 Sep 11.
10. **de Leval L**, Feldman AL, Pileri S, Nakamura S, Gaulard P. Extranodal T- and NK-cell lymphomas.

Virchows Archiv. 2023; 482(1), 245-264.

11. Feldman AL, Laurent C, Narbaitz M, Nakamura S, Chan WC, **de Leval L**, Gaulard P. Classification and diagnostic evaluation of nodal T- and NK-cell lymphomas. *Virchows Archiv.* 2023; 482(1), 265-279.
12. Ondrejka SL, Amador C, Climent F, Ng SB, Soma L, Zamo A, Dirnhofer S, Quintanilla-Martinez L, Wotherspoon A, Leoncini L, **de Leval L**. Follicular helper T-cell lymphomas: disease spectrum, relationship with clonal hematopoiesis, and mimics-a report of the 2022 EA4HP/SH lymphoma workshop. *Virchows Archiv.* 2023; 483(3):349-365.
13. Quintanilla-Martinez L, Laurent C, Soma L, Ng SB, Climent F, Ondrejka SL, Zamo A, Wotherspoon A, **de Leval L**, Dirnhofer S, Leoncini L. Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas: a report of the 2022 EA4HP/SH lymphoma workshop. *Virchows Archiv.* 2023; 483(3):281-298.
14. Di Napoli A, Soma L, Quintanilla-Martinez L, **de Leval L**, Leoncini L, Zamò A, Ng SB, Ondrejka SL, Climent F, Wotherspoon A, Dirnhofer S. Cavity-based lymphomas: challenges and novel concepts. A report of the 2022 EA4HP/SH lymphoma workshop. *Virchows Archiv.* 2023; 483(3):299-316.
Erratum in: *Virchows Archiv.* 2023 Sep 25.
15. Climent F, Nicolae A, **de Leval L**, Dirnhofer S, Leoncini L, Ondrejka SL, Soma L, Wotherspoon A, Zamo A, Quintanilla-Martinez L, Ng SB. Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop. *Virchows Archiv.* 2023; 483(3):333-348.
16. Poon L, **de Leval L**, Ng SB, Song Y, Pro B, Savage KJ, Ruan J, Mehta-Shah N, Vose JM. Hematological Oncology journal women in lymphoma special issue: Latest updates in nodal peripheral T-cell lymphoma. *Hematological oncology.* 2023;10.1002/hon.3191.
17. Bisig B, Savage KJ, **de Leval L**. Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions. *Haematologica.* 2023;108(12):3227-3243.
18. **de Leval L**, Bisig B. What is new in the classification of peripheral T cell lymphomas? *Pathologie (Heidelberg, Germany).* 2024; 44(Suppl 3):128-135.
19. Dewarrat N, Costanza M, Royer-Chardon C, Zermatten MG, **de Leval L**, Naveiras O, Blum S. Anémie aplasique [Aplastic anemia]. *Revue Medicale Suisse.* 2024; 20(880):1271-1275.
20. Savage KJ, de Leval L. Introduction to the peripheral T-cell lymphoma review series: advances in molecular characterization, classification refinement and treatment optimization. *Haematologica.* 2023;108(12):3204-3210.
Erratum in: *Haematologica* 2024; 109(2):693-694.
21. Bisig B, Lefort K, Carras S, **de Leval L**. Clinical use of circulating tumor DNA analysis in patients with lymphoma. *Human pathology* 2024; 105679. *Epub ahead of print.*

Peer-reviewed conference proceedings

1. **de Leval L**. Breast implant-associated anaplastic large cell lymphoma and other rare T-cell lymphomas. *Hematological Oncology.* 2019; 37 S1:24-29.
2. Fischer A, Moreno N, Interlandi M, Albert TK, Mormann J, Glaser S, Patil P, Balbach S, Wagener R, Bens S, Dahlum S, Göbel C, Graf M, Kremer E, de Faria FW, Melcher V, Hartmann W, Herbrüggen H, Robert S, Dugas M, Walter C, Sandmann S, Varghese J, Rössig C, Schüller U, Tzankov A, Pedersen MB, d'Amore FA, Mellgren K, Kotny U, Kancherla V, Veloza L, Missiaglia E, Fataccioli V, Gaulard P, Burkhardt B, Klapper W, **de Leval L**, Siebert R and Kerl K. Lack of smarcb1 expression characterizes a subset of peripheral t-cell lymphomas enriched in children and young adults. *Hematological Oncology.* 2023; 41: 192-192.

3. Bouska A, Zhang W, Sharma S, Holte H, Shah R, Lone W, Cappelli LV, Fiore D, Gong Q, Heavican-Foral T, Cannatella J, Amador C, Thye Lim S, Kiat Ong C, Feldman A, Du MQ, **de Leval L**, Greiner T, Trøen G, Vodák D, Nakken S, Delabie J, Weinstock D, Pileri S, Laginestra A, Kim K, Pajvani U, Vose J, Weisenburger D, Dave S, Inghirami G, Chan W, and Iqbal J. Integrative genomic and transcriptomic characterization reveals therapeutically targetable vulnerabilities in angioimmunoblastic T-cell lymphoma. *Blood*. 2023; 142 (Supplement 1): 2993.
4. **de Leval L**, Bisig B. New Insights Into the Pathogenesis of T-Cell Lymphoma and How This May Guide Treatment. *Clinical Lymphoma Myeloma and Leukemia*. 2023; vol. 23, Suppl. 1, p. S214.

Books chapters

1. **de Leval L**. Non-Hodgkin Lymphomas: Pathology and Genetics. In: Boffetta P, Hainaut P (eds), *Encyclopedia of Cancer*, 3rd edition, vol. 3, Elsevier, Academic Press. 2019; 48-75.
2. Iqbal J, **de Leval L**. Pathology and Molecular Pathogenesis of T-Cell Lymphoma. In: Lenz G, Salles G (eds) *Aggressive Lymphomas. Hematologic Malignancies*. Springer. 2019; (4)95-141.
3. Sy T, **de Leval L**. Monomorphic epitheliotropic intestinal T-cell lymphoma. In: *WHO Classification of Digestive System Tumours*, 5th Edition, International Agency for Research on Cancer (IARC), Lyon; 2019.
4. Hopfinger G, Herling M, **de Leval L**, Krasniqi F, Reimer P, Schmitz N, Wulf G, Periphäre T-Zell Lymphome: Hinweise zu COVID-19 finden Sie in der COVID-19-Leitlinie. In: *Onkopedia*. 2021.
5. Lemonnier F, Gaulard P, **de Leval L**. Mechanisms of T-cell Lymphomagenesis. In: *FDA Approved Drugs for Relapsed or Refractory PTCL*. In *The Peripheral T-Cell Lymphomas (PTCL)*, edited by OA O'Connor OA, Kim WS, Zinzani PL (eds). Wiley & Sons, Oxford. 2021.
6. Sujobert P, Gaulard P, **de Leval L**. Fundamental Principles of Lymphomagenesis. In: O'Connor OA, Ansell SM, Seymour JF (eds) *Precision Cancer Therapies*, vol. 1, Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies. Wiley & Sons, Oxford. 2023.
7. **de Leval L**, Levy M, Copie-Bergman C. Lymphoid tumours of the stomach. In: Bateman AC, Greenson JK, Lauwers GY, Loughrey MB, Novelli M, Sheahan K, Shepherd NA (eds) *Morson & Dawson's Gastrointestinal Pathology*, 6th edition. Wiley & Sons, Oxford. 2025; (15)313-345.
8. **de Leval L**, Bhagat G. Lymphoid tumours of the small intestine. In: Bateman AC, Greenson JK, Lauwers GY, Loughrey MB, Novelli M, Sheahan K, Shepherd NA (eds) *Morson & Dawson's Gastrointestinal Pathology*, 6th edition. Wiley & Sons, Oxford. 2025; (26)579-611.
9. **de Leval L**, Bhagat G, Copie-Bergman C. Lymphoid tumours of large intestine. In: Bateman AC, Greenson JK, Lauwers GY, Loughrey MB, Novelli M, Sheahan K, Shepherd NA (eds) *Morson & Dawson's Gastrointestinal Pathology*, 6th edition. Wiley & Sons, Oxford. 2025; (40)981-1000.